Hepatitis B

Goldstein, S. T., Zhou, F., Hadler, S. C., Bell, B. P., Mast, E. E., & Margolis, H. S. (2005). A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol, 34(6), 1329-1339. doi:10.1093/ije/dyi206.

Nayagam, S., Thursz, M., Sicuri, E., Conteh, L., Wiktor, S., Low-Beer, D. L., & Hallett, T. B. (2016). Requirements for global elimination of hepatitis B: a modelling study. Lancet Infectious Diseases, 16(12), 1399-1408.

Li, X., Wiesen, E., Diorditsa, S., Toda, K., Duong, T. H., Nguyen, L. H., Nguyen, T. H. (2016). Impact of Adverse Events Following Immunization in Viet Nam in 2013 on chronic hepatitis B infection. Vaccine, 34(6), 869-873. doi:10.1016/j.vaccine.2015.05.067.

Wiesen, E., Diorditsa, S., & Li, X. (2016). Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990-2014. Vaccine, 34(25), 2855-2862.

Haemophilus influenzae type b (Hib), rotavirus and pneumococcal disease

Bourgeois, A. L., Wierzba, T. F., & Walker, R. I. (2016). Status of vaccine research and development for enterotoxigenic Escherichia coli. Vaccine, 34(26), 2880-2886. doi:10.1016/j.vaccine.2016.02.076.

Clark, A., Jauregui, B., Griffiths, U., Janusz, C. B., Bolanos-Sierra, B., Hajjeh, R., Sanderson, C. (2013). TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination. Vaccine, 31 Suppl 3, C19-29. doi:10.1016/j.vaccine.2013.05.045.

Jit, M., Huyen, D. T. T., Friberg, I., Van Minh, H., Kiet, P. H. T., Walker, N., & Fox, K. (2015). Thirty years of vaccination in Vietnam: Impact and cost-effectiveness of the national Expanded Programme on Immunization. Vaccine, 33, A233-A239.

Walker, N., Tam, Y., & Friberg, I. K. (2013). Overview of the Lives Saved Tool (LiST). BMC Public Health, 13 Suppl 3, S1. doi:10.1186/1471-2458-13-S3-S1.

Human papillomavirus (HPV)

Goldie, S. J., O’Shea, M., Campos, N. G., Diaz, M., Sweet, S., & Kim, S. Y. (2008). Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine, 26(32), 4080-4093.

Jit, M., Brisson, M., Portnoy, A., & Hutubessy, R. (2014). Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Global Health, 2(7), E406-E414.

Kim, J. J., Sharma, M., O’Shea, M., Sweet, S., Diaz, M., Sancho-Garnier, H., & Seoud, M. (2013). Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in the Extended Middle East and North Africa (EMENA). Vaccine, 31, G65-G77.

Kim, S. Y., Sweet, S., Chang, J., & Goldie, S. J. (2011). Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden. BMC Infect Dis, 11, 174. doi:10.1186/1471-2334-11-174.

Japanese encephalitis

No VIMC publications currently


Chen, S., Fricks, J., & Ferrari, M. J. (2012). Tracking measles infection through non-linear state space models. Journal of the Royal Statistical Society Series C-Applied Statistics, 61, 117-134.

Simons, E., Ferrari, M., Fricks, J., Wannemuehler, K., Anand, A., Burton, A., & Strebel, P. (2012). Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet, 379(9832), 2173-2178. doi:10.1016/S0140-6736(12)60522-4.

Verguet, S., Johri, M., Morris, S. K., Gauvreau, C. L., Jha, P., & Jit, M. (2015). Controlling measles using supplemental immunization activities: A mathematical model to inform optimal policy. Vaccine, 33(10), 1291-1296.

Meningitis A

Oumar, A. D., Isaie, M., Wilfried, B. B., Yameogo, I., Koussoube, D., Ouedraogo, R., Sangare, L., & Mbaeyi, S. A. (2018). Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt. PLoS One, 13(10), e0206117. doi:10.1371/journal.pone.0206117.

Colombini, A., Trotter, C., Madrid, Y., Karachaliou, A., & Preziosi, M. P. (2015). Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso. Clin Infect Dis, 61 Suppl 5, S473-482. doi:10.1093/cid/civ600.

Karachaliou, A., Conlan, A. J., Preziosi, M. P., & Trotter, C. L. (2015). Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt. Clin Infect Dis, 61 Suppl 5, S594-600. doi:10.1093/cid/civ508.

Tartof, S., Cohn, A., Tarbangdo, F., Djingarey, M. H., Messonnier, N., Clark, T. A., Jackson, M. L. (2013). Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt. PLoS One, 8(5), e63605. doi:10.1371/journal.pone.0063605.


Vynnycky, E., Adams, E. J., Cutts, F. T., Reef, S. E., Navar, A. M., Simons, E., Dabbagh, A. J. (2016). Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review.. PLoS One, 11(3).

Vynnycky, E., Yoshida, L. M., Huyen, D. T. T., Trung, N. D., Toda, K., Cuong, N. V., Hien, N. T. (2016). Modeling the impact of rubella vaccination in Vietnam. Human Vaccines & Immunotherapeutics, 12(1), 150-158.

Yellow Fever

Garske, T., Van Kerkhove, M. D., Yactayo, S., Ronveaux, O., Lewis, R. F., Staples, J. E., Comm, Y. F. E. (2014). Yellow Fever in Africa: Estimating the Burden of Disease and Impact of Mass Vaccination from Outbreak and Serological Data. PLoS Med, 11(5).

Jean, K., Donnelly, C. A., Ferguson, N. M., & Garske, T (2016). A Meta-Analysis of Serological Response Associated with Yellow Fever Vaccination. Am J Trop Med Hyg, 95(6), 1435-1439. doi:10.4269/ajtmh.16-0401.